Eli Lilly and Company — EBGLYSS (lebrikizumab-lbkz) - (ADjoin) · Children >12 yo and up with at least 88 pounds (40.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (12/23/25) through T+5. Run-up high $1149.15 on 6/8/26, low $851.21 on 4/30/26 (T-120 to T-1). FDA decision 6/9/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-09
OutcomeApproved
Drug / candidateEBGLYSS (lebrikizumab-lbkz) - (ADjoin)